Marcia Irene Canto1, Tossapol Kerdsirichairat2, Charles J Yeo3, Ralph H Hruban4, Eun Ji Shin2, Jose Alejandro Almario2, Amanda Blackford5, Madeline Ford4, Alison P Klein5, Ammar A Javed6, Anne Marie Lennon2, Atif Zaheer7, Ihab R Kamel7, Elliot K Fishman7, Richard Burkhart6, Jin He6, Martin Makary6, Matthew J Weiss6, Richard D Schulick8, Michael G Goggins2,4, Christopher L Wolfgang6. 1. Division of Gastroenterology and Hepatology, Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Blalock 407, Baltimore, MD, 21287, USA. mcanto1@jhmi.edu. 2. Division of Gastroenterology and Hepatology, Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Blalock 407, Baltimore, MD, 21287, USA. 3. Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA. 4. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 5. Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 6. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 7. Department of Radiology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 8. Department of Surgery, University of Colorado School of Medicine, Denver, CO, USA.
Abstract
BACKGROUND: Screening high-risk individuals (HRI) can detect potentially curable pancreatic ductal adenocarcinoma (PDAC) and its precursors. We describe the outcomes of high-risk individuals (HRI) after pancreatic resection of screen-detected neoplasms. METHODS: Asymptomatic HRI enrolled in the prospective Cancer of the Pancreas Screening (CAPS) studies from 1998 to 2014 based on family history or germline mutations undergoing surveillance for at least 6 months were included. Pathologic diagnoses, hospital length of stay, incidence of diabetes mellitus, operative morbidity, need for repeat operation, and disease-specific mortality were determined. RESULTS: Among 354 HRI, 48 (13.6%) had 57 operations (distal pancreatectomy (31), Whipple (20), and total pancreatectomy (6)) for suspected pancreatic neoplasms presenting as a solid mass (22), cystic lesion(s) (25), or duct stricture (1). The median length of stay was 7 days (IQR 5-11). Nine of the 42 HRI underwent completion pancreatectomy for a new lesion after a median of 3.8 years (IQR 2.5-7.6). Postoperative complications developed in 17 HRI (35%); there were no perioperative deaths. New-onset diabetes mellitus after partial resection developed in 20% of HRI. Fourteen PDACs were diagnosed, 11 were screen-detected, 10 were resectable, and 9 had an R0 resection. Metachronous PDAC developed in remnant pancreata of 2 HRI. PDAC-related mortality was 4/10 (40%), with 90% 1-year survival and 60% 5-year survival, respectively. CONCLUSIONS: Screening HRI can detect PDAC with a high resectability rate. Surgical treatment is associated with a relatively short length of stay and low readmission rate, acceptable morbidity, zero 90-day mortality, and significant long-term survival. CLINICAL TRIAL REGISTRATION NUMBER: NCT2000089.
BACKGROUND: Screening high-risk individuals (HRI) can detect potentially curable pancreatic ductal adenocarcinoma (PDAC) and its precursors. We describe the outcomes of high-risk individuals (HRI) after pancreatic resection of screen-detected neoplasms. METHODS: Asymptomatic HRI enrolled in the prospective Cancer of the Pancreas Screening (CAPS) studies from 1998 to 2014 based on family history or germline mutations undergoing surveillance for at least 6 months were included. Pathologic diagnoses, hospital length of stay, incidence of diabetes mellitus, operative morbidity, need for repeat operation, and disease-specific mortality were determined. RESULTS: Among 354 HRI, 48 (13.6%) had 57 operations (distal pancreatectomy (31), Whipple (20), and total pancreatectomy (6)) for suspected pancreatic neoplasms presenting as a solid mass (22), cystic lesion(s) (25), or duct stricture (1). The median length of stay was 7 days (IQR 5-11). Nine of the 42 HRI underwent completion pancreatectomy for a new lesion after a median of 3.8 years (IQR 2.5-7.6). Postoperative complications developed in 17 HRI (35%); there were no perioperative deaths. New-onset diabetes mellitus after partial resection developed in 20% of HRI. Fourteen PDACs were diagnosed, 11 were screen-detected, 10 were resectable, and 9 had an R0 resection. Metachronous PDAC developed in remnant pancreata of 2 HRI. PDAC-related mortality was 4/10 (40%), with 90% 1-year survival and 60% 5-year survival, respectively. CONCLUSIONS: Screening HRI can detect PDAC with a high resectability rate. Surgical treatment is associated with a relatively short length of stay and low readmission rate, acceptable morbidity, zero 90-day mortality, and significant long-term survival. CLINICAL TRIAL REGISTRATION NUMBER: NCT2000089.
Entities:
Keywords:
Early detection; Pancreatic cancer; Screening; Surgical outcomes
Authors: Charles Mahlon Vollmer; Norberto Sanchez; Stephen Gondek; John McAuliffe; Tara S Kent; John D Christein; Mark P Callery Journal: J Gastrointest Surg Date: 2011-11-08 Impact factor: 3.452
Authors: Elizabeth C Verna; Caroline Hwang; Peter D Stevens; Heidrun Rotterdam; Stavros N Stavropoulos; Carolyn D Sy; Martin A Prince; Wendy K Chung; Robert L Fine; John A Chabot; Harold Frucht Journal: Clin Cancer Res Date: 2010-09-28 Impact factor: 12.531
Authors: Richard A Burkhart; Susan M Gerber; Renee M Tholey; Kathleen M Lamb; Anitha Somasundaram; Caitlin A McIntyre; Eliza C Fradkin; Annie P Ashok; Robert F Felte; Jaya M Mehta; Ernest L Rosato; Harish Lavu; Serge A Jabbour; Charles J Yeo; Jordan M Winter Journal: J Gastrointest Surg Date: 2014-10-15 Impact factor: 3.452
Authors: Emmy Ludwig; Sara H Olson; Sharon Bayuga; Jennifer Simon; Mark A Schattner; Hans Gerdes; Peter J Allen; William R Jarnagin; Robert C Kurtz Journal: Am J Gastroenterol Date: 2011-04-05 Impact factor: 10.864
Authors: Hans Vasen; Isaura Ibrahim; Carmen Guillen Ponce; Emily P Slater; Elvira Matthäi; Alfredo Carrato; Julie Earl; Kristin Robbers; Anneke M van Mil; Thomas Potjer; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Wilma Bergman; Martin Wasser; Hans Morreau; Günter Klöppel; Christoph Schicker; Martin Steinkamp; Jens Figiel; Irene Esposito; Evelina Mocci; Enrique Vazquez-Sequeiros; Alfonso Sanjuanbenito; Maria Muñoz-Beltran; José Montans; Peter Langer; Volker Fendrich; Detlef K Bartsch Journal: J Clin Oncol Date: 2016-04-25 Impact factor: 44.544
Authors: Richard S Swanson; Christopher M Pezzi; Katherine Mallin; Ashley M Loomis; David P Winchester Journal: Ann Surg Oncol Date: 2014-09-05 Impact factor: 5.344
Authors: Detlef Klaus Bartsch; Elvira Matthäi; Ioannis Mintziras; Christian Bauer; Jens Figiel; Mercede Sina-Boemers; Thomas M Gress; Peter Langer; Emily P Slater Journal: Dtsch Arztebl Int Date: 2021-03-05 Impact factor: 5.594
Authors: S González-Santiago; T Ramón Y Cajal; E Aguirre; J E Alés-Martínez; R Andrés; J Balmaña; B Graña; A Herrero; G Llort; A González-Del-Alba Journal: Clin Transl Oncol Date: 2019-12-30 Impact factor: 3.405
Authors: Toshiya Abe; Chiho Koi; Shiro Kohi; Ki-Byung Song; Koji Tamura; Anne Macgregor-Das; Naoki Kitaoka; Miguel Chuidian; Madeline Ford; Mohamad Dbouk; Michael Borges; Jin He; Richard Burkhart; Christopher L Wolfgang; Alison P Klein; James R Eshleman; Ralph H Hruban; Marcia Irene Canto; Michael Goggins Journal: Clin Gastroenterol Hepatol Date: 2019-10-30 Impact factor: 11.382
Authors: Michael Goggins; Kasper Alexander Overbeek; Randall Brand; Sapna Syngal; Marco Del Chiaro; Detlef K Bartsch; Claudio Bassi; Alfredo Carrato; James Farrell; Elliot K Fishman; Paul Fockens; Thomas M Gress; Jeanin E van Hooft; R H Hruban; Fay Kastrinos; Allison Klein; Anne Marie Lennon; Aimee Lucas; Walter Park; Anil Rustgi; Diane Simeone; Elena Stoffel; Hans F A Vasen; Djuna L Cahen; Marcia Irene Canto; Marco Bruno Journal: Gut Date: 2019-10-31 Impact factor: 23.059
Authors: Bechien U Wu; Eva Lustigova; Qiaoling Chen; Elizabeth Y Dong; Anirban Maitra; Suresh T Chari; Ziding Feng; Jo Ann Rinaudo; Lynn M Matrisian; Rex A Parker Journal: Clin Transl Gastroenterol Date: 2022-06-01 Impact factor: 4.396